Analytical Data
-
Gene name
CYP3A2
- Application
-
Alternative Names
CYPIIIA2; Cytochrome P450/6-beta-A; Testosterone 6-beta-hydroxylase; Cytochrome P450-PCN2
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05183
-
Expression Region
Met1~Asn280
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP3A2, a member of the cytochrome P450 family, plays a crucial role in drug metabolism and the biotransformation of various endogenous and exogenous compounds. Its expression is primarily observed in the liver but can also be found in other tissues, and it significantly contributes to the metabolic clearance of a wide range of pharmaceuticals, including analgesics, antiepileptics, and immunosuppressants. Due to its importance in personalized medicine and drug interactions, understanding the structure and function of CYP3A2 is essential for predicting drug metabolism variations in individuals. Moreover, the recombinant protein of CYP3A2 is invaluable for studying enzyme kinetics, elucidating substrate preferences, and assessing the impact of genetic polymorphisms. Advancements in recombinant DNA technology have enabled the production of CYP3A2 in heterologous systems, facilitating detailed biochemical analyses and high-throughput screening for novel drug candidates. Investigating the catalytic mechanisms and regulatory pathways of CYP3A2 through its recombinant form can provide insights into drug-drug interactions and metabolic disease implications, ultimately supporting the development of safer and more effective therapeutic strategies.
